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Abstract Polyketides are important bioactive natural products
biosynthesized by bacteria, fungi, and plants. The enzymes that
synthesize polyketides are collectively referred to as polyketide
synthases (PKSs). Because many of the natural hosts that
produce polyketides are difficult to culture or manipulate,
establishing a universal heterologous host that is genetically
tractable has become an important goal toward the engineered
biosynthesis of polyketides and analogues. Here, we summa-
rize the recent progresses in engineering Escherichia coli as a
heterologous host for reconstituting PKSs of different types.
Our increased understanding of PKS enzymology and
structural biology, combined with new tools in protein
engineering, metabolic engineering, and synthetic biology,
has firmly established E. coli as a powerful host for producing
polyketides.
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Introduction
Polyketides constitute an important family of structurally
diverse natural products, which include many clinicallyuseful
drugs such as the antibiotics erythromycin and tetracycline,
anticancer epothilone, and the anti-hypercholesterolemia
lovastatin. The pharmaceutical values of many polyketides
have led to intense efforts in recent decades toward
understanding and engineering the corresponding biosynthetic
pathways. These concerted efforts from several disciplines,
such as biochemistry, structural biology, genetics, and meta-
bolic engineering, have enabled many examples of rational and
combinatorial biosynthesis of “unnatural” natural products, as
well as enzymatic tools that can be used in the semisynthesis of
natural product-derived targets (Baltz 2006;W e i s s m a na n d
Leadlay 2005; Olano et al. 2009).
Polyketides are synthesized by a family of multifunctional
enzymes known as polyketide synthases (PKSs). PKSs
assemble the core structures (or aglycons) of polyketides via
the sequential Claisen-like condensations of extender units
derived from caboxylated acyl-CoA precursors, in a head-to-
tail fashion (Staunton and Weissman 2001). Based on the
structures of the polyketide products, as well as biochemical
features of the PKSs, PKSs are currently classified into types
I, II, and III subgroups. Type I PKSs are megasynthases in
which catalytic domains are typically found in a single
polypeptide. A modular type I PKS, such as the 6-
deoxyerythronolide B synthase (DEBS) (Donadio and Katz
1992), consists of multiple modules and each module
catalyzes one round of chain elongation and modification.
Linear juxtaposition of modules facilitates unidirectional
transfer of the growing polyketide from the upstream to the
downstream modules in assembly line-like fashion (Cane et
al. 1998). An iterative type I PKS, such as the lovastatin
nonaketide synthase (LovB) (Kennedy et al. 1999), is a
monomodule megasynthase in which a single set of catalytic
domains are used repeatedly in a highly programmed
fashion. Type II PKSs (also known as bacterial aromatic
PKSs) are composed of mostly dissociated, monofunctional
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β-ketone backbone (Hertweck et al. 2007). Type II PKSs are
involved in the synthesis of aromatic polyketides, such as the
aglycons of actinorhodin (McDaniel et al. 1993)a n d
daunorubicin (Hutchinson 1997). In both type I and II PKSs,
the minimal PKS components that are required to perform
one round of decarboxylative condensation consist of a
β-ketoacylsynthase (KS), an acyltransferase (AT), and a
phosphopantethienylated acyl carrier protein (ACP)
(Fig. 1). The elongated polyketide product synthesized
by the minimal PKS can be tailored by enzymes such as
ketoreductase (KR), dehydratase (DH), enoylreductase
(ER) or methyltransferase (MT), etc. Type III PKSs, such as
chalcone synthase (Austin and Noel 2003), are homodimeric
KSs that synthesize smaller aromatic compounds in bacteria,
fungi, and plants. Products synthesized by the various types
of PKSs can undergo different sets of post-PKS modifica-
tions by decorative enzymes encoded in the biosynthetic
pathways, such as cyclases, oxygenases, glycosyltrans-
ferases, etc., to afford the structurally diverse natural
products (Olano et al. 2010).
Polyketides are synthesized mostly by soil-borne or
marine actinomycetes bacteria and filamentous fungi. Type
III polyketides can also be synthesized by plants. While
these organisms can be prolific and impressive natural
product chemists, many of them are unfortunately difficult
to work with in both laboratory and industrial settings. The
difficulties can be attributed to one of more of the following
reasons: (1) the strain is difficult to culture (long doubling
times) or domesticate; (2) the strain is genetically intractable
and refractory toward common molecular biology tools; and
(3) the polyketide biosynthetic pathways are weakly
expressed or silent under laboratory culturing conditions,
resulting in low polyketide titers. To overcome these limi-
tations, one important goal toward engineered biosynthesis of
polyketides is the establishment of robust heterologous hosts
(Pfeifer and Khosla 2001).
The workhorse organism Escherichia coli has emerged
to be a useful heterologous host for the reconstitution,
manipulation, and optimization of polyketide biosynthesis
in recent years. The choice of E. coli is an obvious one
from the start due to the (1) ease of culturing and fast
growth characteristics; (2) availability of superior genetic
tools; (3) well-understood primary metabolism; and (4) the
lack of endogenous polyketide pathways that may crosstalk
or interfere with transplanted pathways. However, E. coli
also has significant drawbacks as a heterologous host,
including lack of compatible post-translational enzymes,
such as the phosphopantetheinyl transferase that canmodify
foreign ACPs (Quadri et al. 1998); unavailability of polyke-
tide building blocks; and difficulties in efficient translation
and functional folding of key biosynthetic components, such
as megasynthases and the P450 family of enzymes.
Fortunately, many of these limitations have been addressed
in recent years via metabolic engineering, protein engineer-
ing, and synthetic biology efforts. As a result, polyketides
synthesized by all three types of PKSs have been produced
in E. coli. While some compounds are only synthesized at
Fig. 1 General mechanisms
involved in polyketide
biosynthesis. KS ketosynthase,
AT acyl transferase, ACP acyl
carrier protein, KR ketoreductase,
ER enoylreductase, DH
dehydratase
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been produced at nearly gram per liter titers after optimiza-
tion (Murli et al. 2003; Leonard et al. 2008). In addition,
using enzymes mined from the biosynthetic pathways, E.
coli has also been engineered to be a platform for
biocatalytic synthesis of polyketide-based, clinically relevant
drugs (Xie et al. 2007). These successes represent important
milestones in outfitting E. coli as a powerful host for
polyketide biosynthesis, and a few of these examples will be
highlighted in this minireview.
Biosynthesis of type I PKS in E. coli—
the 6-deoxyerythronolide B synthase success story
The most successful example of using E. coli as a
heterologous host for polyketide biosynthesis is that of the
total biosynthesis of 6-deoxyerythronolide B (6-dEB) and
erythromycin (Pfeifer et al. 2001). 6-dEB is the 14-
membered macrocyclic core of the antibiotic erythromycin
synthesized by Saccharopolyspora erythraea. The PKS that
synthesizes 6-dEB is DEBS, which consists of three large
polypeptides, each exceeding 300 kDa in molecular weight.
Together, DEBS contains one loading module and six
extension modules, utilizes propionyl-CoA as a starter unit
and six (2S)-methylmalonyl-CoA as extender units (Fig. 2).
Each module (DEBS module 1, module 2, etc.) is responsible
foronechainextensioncycle,aswellasthereductivetailoring
of resulting β-keto product. At the end of the biosynthetic
assembly, a thioesterase (TE) domain fused to the C-terminus
of module 6 catalyzes the macrocyclization of the linear
polyketide to yield 6-dEB (Khosla et al. 2007). The cyclized
6-dEB is then modified by a series of post-PKS enzymes,
including hydroxylation and glycosylation, to yield the
bioactive natural products erythromycin A–D.
Since the initial discovery of the ery genes that encode
DEBSs (Cortes et al. 1990; Donadio et al. 1991), DEBS has
served as the model system to study and engineer modular
type I PKSs. The linear arrangement of domains and
modules inspired the colinearity rule, which allows precise
prediction and manipulation of the product structure from
PKS protein sequence for most of the modular PKSs.
Numerous 6-dEB, erythromycin, and other analogues were
synthesized through domain/module deletions, insertions,
and replacements (Cane 2010). These efforts were first
performed in the natural producer S. erythraea (Marsden et
al. 1998) and model Streptomyces hosts (Kao et al. 1994;
Xue et al. 1999) with great success. However, despite these
efforts, an E. coli platform for producing 6-dEB and
manipulation of DEBS was still being sought after. Pfeifer
et al. reported the first total biosynthesis of 6-dEB in a
highly engineered E. coli strain in 2001 (Pfeifer et al.
2001). Much of the strain engineering was focused on
correctly functionalize the DEBS proteins and transplanting
pathways for accumulation of the methylmalonyl-CoA
building blocks. First, the sfp gene from Bacillus subtilis
(Lambalot et al. 1996) was integrated into the chromosome
of E. coli under a T7 promoter to assure the complete
phosphopantetheinylation of the seven ACP domains in
recombinant DEBS. To increase the concentrations of
propionyl-CoA and methylmalonyl-CoA, the propionate
catabolismgenes inthe prpRBCD operon were deleted, while
a T7 promoter was inserted before the prpE gene, of which
the encoded PrpE can convert propionate to propionyl-CoA.
The resulting strain was named BAP1 and will also be
mentioned later in this review. In addition, the propionyl-
CoA carboxylase (pcc)g e n ef r o mStreptomyces coelicolor
was coexpressed to produce (2S)-methylmalonyl-CoA from
propionyl-CoA. Therefore, both (2S)-methylmalonyl-CoA
and propionyl-CoA can be synthesized and accumulated
inside BAP1 when exogenous propionate was supplied.
Upon transformation of the plasmids that encode all
three of the DEBS megasynthases, 6-dEB was successfully
produced in E. coli for the first time at a titer of 20 mg/L. 6-
dEB was produced ~100 mg/L by high cell density fed-
batch fermentation upon the coexpression of an accessory
thioesterase TEII from S. erythraea (Pfeifer et al. 2002).
Lau et al. found that excess ammonia concentration
dramatically decreased the E. coli cell productivity; hence,
ammonia was maintained below 40 mM throughout the
fermentation process, while high phosphate concentration
was maintained to support cell growth (Lau et al. 2004).
When DEBS proteins were expressed in BAP1 from two
plasmids (Murli et al. 2003) of different origins of
replications, the titer was further improved to 1.1 g/L,
which was comparable to that by the best S. coelicolor host.
Many metabolic engineering efforts that aim at improv-
ing the yield of 6-dEB soon followed the initial success by
Pfeifer and Khosla. For example, the B12-dependent
methylmalonyl-CoA mutase-epimerase pathway from
Propionibacterium shermanii was introduced into BAP1
(Dayem et al. 2002)( F i g .2). This pathway can first
convert succinyl-CoA to (2R)-methylmalonyl-CoA, which
can then be epimerized to (2S)-methylmalonyl-CoA. The
advantage of this pathway is that the extender unit (2S)-
methylmalonyl-CoA can be provided independently of the
starter unit propionyl-CoA. Wang et al. overexpressed the S-
adenosylmethionine synthetase MetK from Streptomyces
spectabilis, and the specific production of 6-dEB was
improved from 10.86 to 20.08 mg/L/OD600 (Wang et al.
2007). The authors attributed the improvement in 6-dEB
titers to the increased synthesis of signaling molecules such
as AI-2. Recently, Zhang et al. deleted E. coli ygfH gene,
which encodes the propionyl-CoA:succinate CoA transferase
and increased 6-dEB titer in the parent strain from 65 to
129 mg/L under shake flask conditions (Zhang et al. 2010).
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(pccB and accA1) and the entire genes encoding DEBS
(~30 kb) into the E. coli chromosome to create a plasmid-
free strain YW9. This strain produced 6-dEB at a titer of
0.52 mg/L at 30°C and remarkably can produce 0.11 mg/L
6-dEB in E. coli even at 37°C. Some other metabolic
engineering attempts, including overexpressing the E.
coli methylmalonyl-CoA mutase, sbm, or deleting the
methylmalonyl-CoA decarboxylase ygfG,d i dn o th a v ea n
positive impact on the production of 6-dEB. Similarly,
overexpressing the malonyl/methylmalonyl-CoA ligase
(MatB) pathway also did not lead to any improvement,
although methylmalonyl-CoA was accumulated to 90% of
the intracellular acyl-CoA pool (Murli et al. 2003).
Utilizing the E. coli platform, Pfeifer et al. (2001) were
able to generate an analogue of 6-dEB by replacing the
loading module with that from rif PKS. Taking advantage
of the broad substrate specificity of the DEBS loading
didomain, Kennedy et al. (2003) overexpressed the
acetoacetyl-CoA:acetyl-CoA transferase AtoD in E. coli.
When butyrate was supplied, butyryl-CoA was synthesized
as the starter unit and the corresponding 6-dEB analogue
(15-methyl-6-dEB) was generated by E. coli. Furthermore,
by inactivating the loading didomain of DEBS followed by
supplementation of various acyl-thioesters starter units,
additional 6-dEB analogues were produced (Murli et al.
2005).
To complete erythromycin biosynthesis in E. coli,P e i r ue t
al. identified 16 genes from the megalomicin (meg)
biosynthetic pathway that encoded the tailoring enzymes
that can convert 6-dEB to erythromycin C, as well as a
rRNA methyltransferase (ErmE) that was necessary to confer
host self-resistance (Peiru et al. 2005). Two additional
plasmids encoding the L-mycarose and D-desosamine
operons were constructed. The L-mycarose operon contains
genes necessary for synthesis of TDP-L-mycarose, a
Fig. 2 Biosynthesis of 6-dEB and erythromycin
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6dEB 6-hydroxylase; whereas the D-desosamine operon
contains genes required for the synthesis of TDP-D-
desosamine, a TDP-D-desosamine glycosyltransferase,
and 6dEB 12-hydroxylase. Then, an engineered E. coli
strain expressing DEBS and all the necessary tailoring
enzymes (23 genes in total) was constructed, which
produced the antibacterial erythromycin C at a titer of
0.4 mg/L and erythromycin D at that of 0.5 mg/L. The
final conversion to the most desired erythromycin A,
which requires the action of an O-methyltransferase, has
not been achieved to date.
Biosynthesis of other complete and partial type
I polyketides in E. coli
Epothilones are potent anticancer agents (tubulin inhibitors)
that were originally isolated from Sorangium cellulosum
(Bollag et al. 1995). Epothilones are synthesized by a
hybrid PKS-nonribosomal peptide synthetases (NRPS)
pathway. The NRPS module synthesizes the thiazole
portion of the molecule, while the PKS portion assembles
the macrolide core. The 56-kb epo gene cluster consists of
one loading module (EpoA), one NRPS module (EpoB),
eight PKS modules in three polypeptides (EpoD, EpoE, and
EpoF) and a P450 epoxidase (EpoK) (Julien et al. 2000;
Tang et al. 2000). The size of the entire cluster therefore
presents a challenge to reconstitute in E. coli. Boddy et al.
(2004) used a precursor directed method to first demonstrate
epothilone production from the BAP1 strain. This was
accomplished using a three-plasmid system to express EpoD
module 6, EpoE, and EpoF in soluble forms. To mimic the
upstream substrate of EpoD module 6, an advanced N-acetyl
cysteamine (SNAC) thioester precursor was synthesized to
be recognized by the KS domain of module 6. When the
precursor was supplemented to the BAP1 strain, epothilone
C was produced at a titer of 0.7 mg/L, which is comparable
to that of the wild-type native host.
Subsequently, Mutka et al. (2006) expressed the full-
length epo PKS-NRPS in E. coli and observed production
of epothilone C and D. To accomplish this milestone,
difficulties in molecular biology were first overcome
through custom gene synthesis and strategic restriction site
placement. At the same time, the GC-rich epo genes were
codon optimized to ensure efficient translation. To further
improve the protein expression and folding, the T7
promoter was changed to the arabinose-inducible PBAD
promoter, and chaperone proteins were coexpressed. Soluble
expressionoflargerportionsoftheepo PKS modules allowed
them to perform the precursor-directed biosynthesis using
much simpler SNAC-based substrates. Feeding of (E)-2-
methyl-3-(2-methylthiazol-4-yl) acrylic acid to BAP1encoding
the last seven modules (EpoD, EpoE, and EpoF) of the epo
biosynthetic pathway resulted in the expected synthesis of
epothilone C. With this platform, novel epothilone analogues
can be generated in a more straightforward fashion through
the feeding of custom-synthesized precursors. The epothilone
example therefore shows that synthetic biology approaches
can play key roles in overcoming difficulties associated with
reconstitution of large pathway into E. coli.
The epothilone PKS currently represents the largest
modular type I PKS reconstituted in E. coli. Other large
macrolides require more PKS modules and therefore are
even more daunting obstacles. One such example is the
important antibacterial agent rifamycin, of which the
biosynthetic gene cluster is ~90 kb (Schupp et al. 1998;
August et al. 1998). The biosynthesis pathways of
rifamycin and other ansamycins are primed by 3-amino-5-
hydroxybenzoic acid (AHBA), which is synthesized by a
dedicated metabolic pathway consists of seven enzymes.
AHBA then serves as the starter unit for the first
megasynthases in the rif pathway, RifA, which is a
~530 kDa NRPS/PKS megasynthases and cannot be solubly
expressed in E. coli. Toward heterologously reconstituting
the rif pathway in BAP1, Khosla and coworkers first
successfully expressed a cassette of seven genes to produce
AHBA. Among them, two of the genes were cloned from the
ansamycin pathway because the corresponding RifG and
RifJ cannot be expressed solubly (Watanabe et al. 2003). To
overcome the enormous size of RifA, the same research
group first dissected RifA into two smaller, bimodular
enzymes (~240 and ~290 kDa). To subsequently reestablish
communication and substrate transfer between the separated
proteins, intermodular peptide linkers from the DEBS
pathway (those between DEBS modules 2 and 3) were
appended to the C- and N-termini of the upstream and
downstream RifA modules, respectively (Watanabe et al.
2003). This linker approach is an important strategy that can
be used to split otherwise unmanageable megasynthases into
considerably smaller pieces while maintaining the crucial
crosstalk and specificity. Finally, by combining the AHBA
pathway and the reengineered RifA parts, the key interme-
diate P8_1-OG was produced in BAP1 at a titer of 2.5 mg/L.
Biosynthesis of type II polyketides in E. coli
In contrast to the success of reconstituting type I PKSs, E.
coli has been a complete disappointment as a host for type
II PKSs from actinomycete despite intense efforts by many
groups. The main obstacle is the insoluble expression of the
KSa  KSb heterodimer (combined size of ~90 kDa),
which is part of the minimal PKS and synthesizes the full
poly-β-ketone backbone (Hertweck et al. 2007). KSa is the
active subunit and catalyzes the repeated Claisen-like
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length determination (Tang et al. 2003). Different attempts
to express KSa  KSb solubly in E. coli, including
translational fusion to other proteins, to each other, or to
dimerizing peptides, have all resulted in 100% of the highly
expressed complex residing in the insoluble fraction of E.
coli total protein. The exact reason for the insoluble
expression is not known, but we hypothesize that it could
be due to incompatibilities between the rates of protein
synthesis, subunit folding, and heterodimerization, the latter
of which is likely the most important factor.
Recently, our group engineered a fungal nonreducing
PKScapableofsynthesizingthepoly-β-ketonebackboneinE.
coli, thereby indirectly bypassed the need for soluble KSa 
KSb expression (Zhang et al. 2008). Using the bikaverin
synthase PKS4 from Gibberella fujikuroi (Linnemannstons et
al. 2002), which is a megasynthase that can be expressed
solubly in E. coli (Ma et al. 2007), Ma and coworkers first
showed that ketoreductase (act KR) and cyclases associated
with bacterial type II PKS can modify the polyketide
backbone synthesized by PKS4. However, the built-in
product template (PT) domains of PKS4 cyclized most of
the products in a fungal-specific regioselectivity, which is
considerably different than those of type II PKS products
(Thomas 2001). To inactivate the built-in, fungal-specific
cyclization activities of PKS4, Zhang et al. extracted the
minimal PKS components (including the KS-AT didomain
and ACP) from PKS4 (Zhang et al. 2008). These components
wereefficient in synthesizinga complete nonaketidebackbone
in E. coli. Combining the PKS4 minimal PKS with an
assortment of type II PKS tailoring enzymes led to the
synthesis of compounds in BAP1 that were previously only
observed from Streptomyces, including PK8 (Kramer et al.
1997) and SEK26 (McDaniel et al. 1995). The E. coli
platform can be easily scaled up under fermentation
conditions and afforded milligram quantities of aromatic
polyketides. Other fungal nonreducing PKSs of different
chain-length specificities may be similarly engineered
toward the synthesis of aromatic polyketides of different
sizes in E. coli.
Biosynthesis of plant type III polyketides in E. coli
The type III PKSs provide the key structural scaffolds of a
variety of plant secondary metabolites by catalyzing
decarboxylative condensation between the starter unit, such
as p-coumaroyl-CoA or cinnamoyl-CoA, and the extended
unit malonyl-CoA. Depending on the specific activities of
the type III PKSs, the product can be cyclized into different
structures. The chalcone synthases (CHS) cyclize the
products into flavanones, which can be further modified
into to a variety of flavonoids (Weisshaar and Jenkins
1998). Stilbene synthase (STS) can cyclize the polyketide
via a different regioselectivity to produce the stilbene
backbone, which is the key intermediate in the biosynthesis
of stilbenoids (Austin et al. 2004). Curcuminoid synthase
(CUS) represents the non-cyclization type of type III PKSs
that only catalyzes condensation reactions to generate
curcuminoids (Abe and Morita 2010).
Horinouchi and coworkers used E. coli as a heterologous
host for different plant type III PKSs and generated libraries
of plant-specific polyketides from both simple amino acid
and carboxylic acid precursors using different type III PKSs.
First, an E. coli strain was engineered to overexpress
phenylalanine ammonia lyase (PAL) from Rhodotorula
rubra and 4-coumarate:coenzyme A ligase (4CL) from S.
coelicolor A3(2). When supplemented with phenylalanine or
tyrosine, the required starter units cinnamoyl-CoA or
p-coumaroyl-CoA can be produced, respectively. Using
this host, coexpression of CHS from the licorice plant
Glycyrrhiza echinata resulted in the productions of
pinocembrin chalcone and naringenin chalcone (Fig. 3;
Hwang et al. 2003; Miyahisa et al. 2005). Similarly,
resveratrol and pinosylvin were synthesized by replacing
CHS with Arachis hypogaea STS and overexpressing
Corynebacterium glutamicum acetyl-CoA carboxylase
(ACC) (Fig. 3; Katsuyama et al. 2007b). Finally, the
coexpression of PAL, 4CL, CUS, and ACC in E. coli
produced bisdemethoxycurcumin and dicinnamoylmethane
(Fig. 3; Katsuyama et al. 2008). Hence, once a pathway for
the biosynthesis of precursors is established, the E. coli host
can be directed toward the synthesis of different type III
polyketides by varying the choice of the key PKS.
To produce structurally more diverse compounds,
precursor-directed biosynthesis strategy was performed
based on the above system. Various aromatic carboxylic
acids were supplied and led to the synthesis of
corresponding unnatural compounds (Katsuyama et al.
2007a, 2010). Additional coexpression of post-PKS mod-
ification enzymes introduced by a multi-plasmid approach
can further tailor the natural or unnatural flavonols,
flavones, methylated resveratrols, etc. (Miyahisa et al.
2006; Leonard et al. 2006; Yan et al. 2007).
To improve titer of flavanone biosynthesis in E. coli,
Koffas and coworkers designed a series of experiments to
optimize the availability of the key building block malonyl-
CoA. Malonyl-CoA can be synthesized from acetyl-CoA
by the enzyme ACC using biotin as a cofactor. First, ACC
from Photorhabdus luminescens was coexpressed with
Petroselinum crispum 4CL, Petunia hybrida CHS, and
Medicago sativa CHI, which resulted in the production of
pinocembrin and naringenin with titers of 196 and 67 mg/L,
respectively. Second, the biotin ligase (BPL) from P.
luminescens was coexpressed and improved the titer of
pinocembrin to 367 mg/L. Third, overexpression of E. coli
1238 Appl Microbiol Biotechnol (2010) 88:1233–1242endogenous acetyl-CoA synthetase resulted in further
improvement of titer of pinocembrin up to 429 mg/L when
supplemented with acetate at low level (Leonard et al.
2007). Alternatively, malonyl-CoA can also be synthesized
from malonyl-CoA synthase MatB from malonate. When
Rhizobium trifolii MatB and dicarboxylate carrier protein
(MatC) were coexpressed with 4CL, CHS, and CHI in E.
coli, which was supplemented with malonate, the maximal
titer of pinocembrin reached 710 mg/L (Leonard et al.
2008). It is worth noting that the high titer was achieved by
also adding 0.2 mM of cerulenin, which suppresses the
activities of FabB/F that competes for the malonyl-CoA
pool for fatty acid biosynthesis.
Biocatalytic synthesis of simvastatin in E. coli
In addition to serving as a heterologous host for the various
PKSs discussed above, E. coli has also been engineered to
catalyze the semisynthesis of important, polyketide-derived
drug molecules. One example is the biocatalytic synthesis
of simvastatin, an important cholesterol-lowing drug, which
is the active ingredient of the blockbuster drug Zocor.
Simvastatin is a statin, which is a family of compounds that
that can inhibit the 3-hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase, the enzyme that catalyzes the rate-
limiting step in the biosynthesis of cholesterol (Freeman
2006). The first statin approved by the FDA, lovastatin
Fig. 3 Biosynthesis of flavonoids, stilbenoids, and curcuminoids
Fig. 4 Synthesis of simvastatin using E. coli as the whole-cell biocatalyst
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terreus (Hendrickson et al. 1999; Kennedy et al. 1999).
Simvastatin is a semi-synthesized derivative of lovastatin and
is a more potent inhibitor of HMG-CoA reductase while
exhibiting considerable less side effects in treating hyper-
cholesterolemia (Manzoni and Rollini 2002). The only
difference between lovastatin and simvastatin is the substi-
tution of α-S-methylbutyrate with α-dimethylbutyrate side
chain at C-8 position of the decaline core (Fig. 4). Currently,
simvastatin is produced by a multistep chemical synthesis
starting from lovastatin.
LovD is an acyltransferase found in the lovastatin
biosynthetic pathway and is responsible for catalyzing
the last step of lovastatin biosynthesis by acylating
monacolin J with the α-S-methylbutyryl side chain
synthesized by an iterative type I PKS LovF (Xie et al.
2009). Therefore, LovD was considered as a potential
enzyme that can transfer a dimethylbutyryl side chain to
monacolin J and afford simvastatin via the biocatalytic
approach. To confirm the activities of LovD, Xie et al.
(2006) cloned and overexpressed LovD in E. coli.L o v D
was shown to regioselectively transfer α-S-methylbutyryl
acyl group to monacolin J to produce lovastatin via a ping-
pong mechanism. The authors demonstrated that LovD
had broad substrate specificities toward the acyl carrier,
the acyl substrate, and the decalin acyl acceptor. For
example, it was able to accept membrane permeable
SNAC thioesters, such as α-dimethyl-butyryl-SNAC
(DMB-SNAC) as the acyl donor. Using E. coli as a
whole-cell biocatalytic host, monacolin J was converted to
simvastatin using a LovD expression strain and feeding of
DMB-SNAC.
To improve the efficiency of the acyltransfer reaction
and decrease the cost of the α-dimethylbutyryl acyl
donor, further optimization of the substrate was per-
formed (Xie and Tang 2007). Among the various
thioesters assayed in this effort, the authors determined
that α-dimethylbutyryl-S-methyl-3-mercaptopropionate
(DMB-SMMP) is a superior substrate considering both
the high initial turnover rate and the low raw material cost
(Fig. 4). When DMB-SMMP was supplemented to the
E. coli host, nearly quantitative conversion (>99%) of
monacolin J to simvastatin was achieved at 6 g/L.
Subsequently, an engineered E. coli strain YT2, which
contains a bioH knockout, was selected as the whole-cell
host (Xie et al. 2007). BioH was previously reported as a
carboxylesterase involved in the biotin biosynthetic pathway
(Sanishvili et al. 2003). It was found that BioH rapidly
hydrolyzed DMB-SMMP into dimethylbutyryl mercaptopro-
pionic acid (DMB-SMPA; Fig. 4), which significantly
lowered the overall turnover rate of the transformation.
Using the YT2 strain as the host, the rate of simvastatin
synthesis was doubled.
Directed evolution was then used to improve the LovD
catalytic activity (Gao et al. 2009). The authors employed a
combination of error prone polymerase chain reaction
(ep-PCR), saturation mutagenesis, and site mutagenesis to
generate LovD variants. E. coli libraries expressing mutant
LovD were obtained, and the whole-cell activities of
converting monacolin J to simvastatin were assayed by
utilizing an agar-based diffusion screening assay. This
method relied on the property that simvastatin inhibited
the growth of the embedded Neurospora crassa. The best
mutant G7 displayed ~11-fold higher increase in whole-cell
activity compared to the wild-type LovD. Using this
mutant, ~30 g/L monacolin J can be quantitatively
converted to simvastatin within 1 day. The authors also
attempted to provide a plausible explanation for the basis of
enhanced catalytic efficiency of LovD by solving the
crystal structures of parent LovD, an improved mutant
G5, and G5 co-crystallized with lovastatin and simvastatin.
Comparisonsbetweenthese structuresrevealedthatbeneficial
mutations promoted a more compact conformation that was
favorable for catalysis. Using the combined strategies of
protein engineering, metabolic engineering, and substrate
optimization,the E. coli based platform is now more efficient,
more cost-effective and environmentally friendlier than the
synthetic approaches previously used in the semisynthesis of
simvastatin.
Conclusions
E. coli is a highly versatile microorganism for recon-
stituting and engineering natural product biosynthetic
pathways. Despite some limitations in protein expression,
building block availability, and intracellular capacity for
lipophilic compounds, combined efforts from different
disciplines of biotechnology have rendered E. coli a
suitable host for many PKSs. With the identification of an
exploding number of biosynthetic pathways from recently
sequenced organisms, engineered E. coli strains discussed
in this review will play more important roles in the
identification, dissection, and manipulation of new PKS
machineries in the future.
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